Affimed Announces Fourth Quarter and Year End 2016 Financial Results and Corporate Update Conference Call
March 23 2017 - 6:01AM
Heidelberg, Germany, March 23, 2017 - Affimed
N.V. (Nasdaq: AFMD) today announced that on March 30, 2017, the
Company will release its financial results for the quarter and year
ended December 31, 2016. The Company's management team will host a
conference call to discuss the Company's financial results and
recent corporate developments on Thursday, March 30, 2017 at 8:30
a.m. ET. The call can be accessed by dialing one of the numbers
listed below five minutes prior to the start of the call and
providing the confirmation code 9811704.
Local -
Amsterdam, the Netherlands: |
+31 (0)
20 721 9158 |
Local -
Copenhagen, Denmark: |
+45 32
71 16 60 |
Local -
Frankfurt, Germany: |
+49 (0)
69 2222 10626 |
Local -
Geneva, Switzerland: |
+41 (0)
22 417 7109 |
Local -
London, U.K.: |
+44 (0)
20 3427 1911 |
Local -
New York City, U.S.A.: |
+1 646
254 3361 |
Local -
Paris, France: |
+33 (0)
1 76 77 22 22 |
An audio webcast of the conference call can be
accessed in the "Events" section on the
"Investors & Media" page of the Affimed website at
http://www.affimed.com/events.php. A replay of the webcast will be
available on Affimed's website shortly after the conclusion of the
call and will be archived on the Affimed website for 30 days
following the call.
About Affimed N.V.Affimed (Nasdaq: AFMD)
engineers targeted immunotherapies, seeking to cure patients by
harnessing the power of innate and adaptive immunity (NK- and
T-cells). We are developing single and combination therapies to
treat cancers and other life-threatening diseases. For more
information, please visit www.affimed.com.
IR Contact:Caroline Stewart, Head IRPhone: +1 347394
6793E-Mail: IR@affimed.com or c.stewart@affimed.com
Media Contact:Anca Alexandru, Head of Communications, EU
IRPhone: +49 6221 64793341E-Mail: a.alexandru@affimed.com
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Sep 2023 to Sep 2024